Abstract
In patients with COVID-19, thromboinflammation is one of the main causes of morbidity and mortality, which makes anticoagulation an integral part of treatment. However, pharmacodynamic and pharmacokinetic properties of direct oral anticoagulants (DOACs) limit the use of this class of anticoagulants in COVID-19 patients due to a significant interference with antiviral agents. DOACs use in COVID-19 hospitalized patients is currently not recommended. Furthermore, patients already on oral anticoagulant drugs should be switched to heparin at hospital admission. Nevertheless, outpatients with a confirmed diagnosis of COVID-19 are recommended to continue prior DOAC therapy. More studies are required to clarify the pathogenesis of COVID-19-induced derangement of the coagulation system in order to recommend an appropriate anticoagulant treatment.
【초록키워드】 COVID-19, Treatment, therapy, Pathogenesis, anticoagulation, drug, heparin, Antiviral agents, morbidity, Patient, Hospital admission, outpatients, morbidity and mortality, Coagulation system, Thromboinflammation, COVID-19 patients, Anticoagulants, Anticoagulant, pharmacokinetic, Outpatient, COVID-19 patient, Anticoagulant treatment, DOACs, DOAC, limit, required, hospitalized patient, cause, diagnosis of COVID-19, oral anticoagulant, patients with COVID-19, 【제목키워드】 antiviral therapy, oral anticoagulant,